Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference CallGlobeNewsWire · 3 days ago
Neuronetics, Inc. (NASDAQ:STIM) Stock Now Rated “Moderate Buy” by Sell-Side BrokeragesDefense World · Oct 6, 2026
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR SystemGlobeNewsWire · Sep 8, 2026
Neuronetics, Inc. (STIM) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 11, 2026
Neuronetics Q2 Earnings Call HighlightsMarketBeat · Aug 11, 2026
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research · Aug 11, 2026Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.12 | -$0.05 | Beat |
| May 5, 2026 | -$0.17 | -$0.16 | Beat |
| Mar 17, 2026 | -$0.12 | -$0.10 | Beat |
| Nov 4, 2025 | -$0.12 | -$0.13 | Miss |
| Aug 5, 2025 | -$0.08 | -$0.15 | Miss |
| May 6, 2025 | -$0.13 | -$0.21 | Miss |